

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
MARTIN GEISER

U.S. APPLICATION NO: 10/528,709

35 USC §371 DATE: March 22, 2005

FOR: ATOMIC STRUCTURE OF THE CATALYTIC DOMAIN FOR USE IN
DESIGNING AND IDENTIFYING INHIBITORS OF ZAP-70 KINASE

Mail Stop: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of August 31, 2007, Applicants elect the claims of Group IV, claims 12-17, drawn to the special technical feature of identifying a ligand or a low molecular weight compound. This election is made without traverse.


The Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Applicants reserve the right to prosecute the subject matter of any non-elected claim groups in one or more divisional applications.

An early and favorable action on the merits is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346



John Prince, Ph.D.
Attorney for Applicants
Reg. No. 43,019

Date: September 26, 2007